Immunotherapy duo takes on Hard-to-Treat brain tumors
NCT ID NCT02648997
First seen Feb 01, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This study tests two immunotherapy drugs, nivolumab alone or combined with ipilimumab, in 40 adults with recurrent or progressive meningioma (a type of brain tumor). The goal is to see if these treatments can stop the tumor from growing for at least six months. Participants must have already tried other treatments like surgery or radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGIOMAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.